Neomycin and plasma lipoproteins in type II hyperlipoproteinemia

Jeffrey M. Hoeg, Ernst J. Schaefer, Carol A. Romano, Ernestina Bou, Anita M. Pikus, Loren A. Zech, Kent R Bailey, Richard E. Gregg, Peter W F Wilson, Dennis L. Sprecher, Alison M. Grimes, Nancy G. Sebring, Elaine J. Ayres, Claus E. Jahn, H. B. Brewer

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9-mo, double-blind, randomized, crossover, placebo-controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safey, was described in 20 subjects with type II hyperlipoproteinemia. A 15% (50 mg%) decline in plasma cholesterol concentration was observed with neomycin. Most of this effect resulted from a 41 mg% (16%) decrease in low-density lipoprotein cholesterol concentration. No significant or consistent effect on the concentration of high-density lipoprotein cholesterol was observed. Monthly audiologic and renal evaluation disclosed no oto- or nephrotoxicity. Neomycin treatment in patients with type 11 hype rlipoproteinemia is an inexpensive and effective means of lowering the concentration of low-density lipoproteins and is free of significant side effects over a 3-mo period.

Original languageEnglish (US)
Pages (from-to)555-565
Number of pages11
JournalClinical Pharmacology and Therapeutics
Volume36
Issue number4
StatePublished - Oct 1984
Externally publishedYes

Fingerprint

Hyperlipoproteinemia Type II
Neomycin
Lipoproteins
Controlled Clinical Trials
Aminoglycosides
LDL Lipoproteins
LDL Cholesterol
HDL Cholesterol
Cholesterol
Placebos
Anti-Bacterial Agents
Kidney
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Hoeg, J. M., Schaefer, E. J., Romano, C. A., Bou, E., Pikus, A. M., Zech, L. A., ... Brewer, H. B. (1984). Neomycin and plasma lipoproteins in type II hyperlipoproteinemia. Clinical Pharmacology and Therapeutics, 36(4), 555-565.

Neomycin and plasma lipoproteins in type II hyperlipoproteinemia. / Hoeg, Jeffrey M.; Schaefer, Ernst J.; Romano, Carol A.; Bou, Ernestina; Pikus, Anita M.; Zech, Loren A.; Bailey, Kent R; Gregg, Richard E.; Wilson, Peter W F; Sprecher, Dennis L.; Grimes, Alison M.; Sebring, Nancy G.; Ayres, Elaine J.; Jahn, Claus E.; Brewer, H. B.

In: Clinical Pharmacology and Therapeutics, Vol. 36, No. 4, 10.1984, p. 555-565.

Research output: Contribution to journalArticle

Hoeg, JM, Schaefer, EJ, Romano, CA, Bou, E, Pikus, AM, Zech, LA, Bailey, KR, Gregg, RE, Wilson, PWF, Sprecher, DL, Grimes, AM, Sebring, NG, Ayres, EJ, Jahn, CE & Brewer, HB 1984, 'Neomycin and plasma lipoproteins in type II hyperlipoproteinemia', Clinical Pharmacology and Therapeutics, vol. 36, no. 4, pp. 555-565.
Hoeg JM, Schaefer EJ, Romano CA, Bou E, Pikus AM, Zech LA et al. Neomycin and plasma lipoproteins in type II hyperlipoproteinemia. Clinical Pharmacology and Therapeutics. 1984 Oct;36(4):555-565.
Hoeg, Jeffrey M. ; Schaefer, Ernst J. ; Romano, Carol A. ; Bou, Ernestina ; Pikus, Anita M. ; Zech, Loren A. ; Bailey, Kent R ; Gregg, Richard E. ; Wilson, Peter W F ; Sprecher, Dennis L. ; Grimes, Alison M. ; Sebring, Nancy G. ; Ayres, Elaine J. ; Jahn, Claus E. ; Brewer, H. B. / Neomycin and plasma lipoproteins in type II hyperlipoproteinemia. In: Clinical Pharmacology and Therapeutics. 1984 ; Vol. 36, No. 4. pp. 555-565.
@article{0191e4f4aa124eb18e5afc37a75af3c5,
title = "Neomycin and plasma lipoproteins in type II hyperlipoproteinemia",
abstract = "Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9-mo, double-blind, randomized, crossover, placebo-controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safey, was described in 20 subjects with type II hyperlipoproteinemia. A 15{\%} (50 mg{\%}) decline in plasma cholesterol concentration was observed with neomycin. Most of this effect resulted from a 41 mg{\%} (16{\%}) decrease in low-density lipoprotein cholesterol concentration. No significant or consistent effect on the concentration of high-density lipoprotein cholesterol was observed. Monthly audiologic and renal evaluation disclosed no oto- or nephrotoxicity. Neomycin treatment in patients with type 11 hype rlipoproteinemia is an inexpensive and effective means of lowering the concentration of low-density lipoproteins and is free of significant side effects over a 3-mo period.",
author = "Hoeg, {Jeffrey M.} and Schaefer, {Ernst J.} and Romano, {Carol A.} and Ernestina Bou and Pikus, {Anita M.} and Zech, {Loren A.} and Bailey, {Kent R} and Gregg, {Richard E.} and Wilson, {Peter W F} and Sprecher, {Dennis L.} and Grimes, {Alison M.} and Sebring, {Nancy G.} and Ayres, {Elaine J.} and Jahn, {Claus E.} and Brewer, {H. B.}",
year = "1984",
month = "10",
language = "English (US)",
volume = "36",
pages = "555--565",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Neomycin and plasma lipoproteins in type II hyperlipoproteinemia

AU - Hoeg, Jeffrey M.

AU - Schaefer, Ernst J.

AU - Romano, Carol A.

AU - Bou, Ernestina

AU - Pikus, Anita M.

AU - Zech, Loren A.

AU - Bailey, Kent R

AU - Gregg, Richard E.

AU - Wilson, Peter W F

AU - Sprecher, Dennis L.

AU - Grimes, Alison M.

AU - Sebring, Nancy G.

AU - Ayres, Elaine J.

AU - Jahn, Claus E.

AU - Brewer, H. B.

PY - 1984/10

Y1 - 1984/10

N2 - Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9-mo, double-blind, randomized, crossover, placebo-controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safey, was described in 20 subjects with type II hyperlipoproteinemia. A 15% (50 mg%) decline in plasma cholesterol concentration was observed with neomycin. Most of this effect resulted from a 41 mg% (16%) decrease in low-density lipoprotein cholesterol concentration. No significant or consistent effect on the concentration of high-density lipoprotein cholesterol was observed. Monthly audiologic and renal evaluation disclosed no oto- or nephrotoxicity. Neomycin treatment in patients with type 11 hype rlipoproteinemia is an inexpensive and effective means of lowering the concentration of low-density lipoproteins and is free of significant side effects over a 3-mo period.

AB - Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9-mo, double-blind, randomized, crossover, placebo-controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safey, was described in 20 subjects with type II hyperlipoproteinemia. A 15% (50 mg%) decline in plasma cholesterol concentration was observed with neomycin. Most of this effect resulted from a 41 mg% (16%) decrease in low-density lipoprotein cholesterol concentration. No significant or consistent effect on the concentration of high-density lipoprotein cholesterol was observed. Monthly audiologic and renal evaluation disclosed no oto- or nephrotoxicity. Neomycin treatment in patients with type 11 hype rlipoproteinemia is an inexpensive and effective means of lowering the concentration of low-density lipoproteins and is free of significant side effects over a 3-mo period.

UR - http://www.scopus.com/inward/record.url?scp=0021683660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021683660&partnerID=8YFLogxK

M3 - Article

C2 - 6383687

AN - SCOPUS:0021683660

VL - 36

SP - 555

EP - 565

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -